脊髄性筋萎縮症 (SMA) ：アジア太平洋地域の主要市場における疫学予測
Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028
|出版日||ページ情報||英文 104 Pages
|脊髄性筋萎縮症 (SMA) ：アジア太平洋地域の主要市場における疫学予測 Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028|
|出版日: 2019年11月29日||ページ情報: 英文 104 Pages||
アジア太平洋地域の主要5ヶ国 (オーストラリア、中国、インド、韓国、日本) で脊髄性筋萎縮症 (SMA) と診断された患者数は、2018年の99,759人から、2028年の99,759人まで、AAR (年間成長率) で0.56％の増加が予測されています。
当レポートでは、アジア太平洋地域の主要5ヶ国における脊髄性筋萎縮症 (SMA) について調査分析し、最新の疫学予測について、体系的な情報を提供しています。
Spinal Muscular Atrophy (SMA) is a rare genetic neurodegenerative disease that primarily affects children. It is characterized by loss of spinal motor neurons, which are specialized cells that control muscle movement. The Spinal Muscular Atrophy (SMA) market across the five growth markets (5GM) Australia, China, India, Japan and South Korea in the Asia-Pacific (APAC) region is anticipated to grow at a compound annual growth rate of 23.3% from US$308.6m in 2018 to US$2.5bn in 2028. Increased uptake of the first disease-modifying Spinal Muscular Atrophy (SMA) therapies will drive the robust growth during the outlook period.
Biogen's antisense therapy Spinraza (nusinersen) was first approved for the treatment of Spinal Muscular Atrophy (SMA) in Japan in June 2017 and has since been approved in Australia, South Korea and China. The approval of this drug is revolutionizing the management of the disease, with clinically meaningful improvements in motor function, achievement of milestones and survival observed for the first time in children with Spinal Muscular Atrophy (SMA).
Spinraza accounted for the vast majority of sales across the (5GM) Australia, China, India, Japan and South Korea in 2018 and sales are projected to remain strong throughout the early-to-mid forecast period (2018-2023). However, Spinraza is projected to lose its monopoly in the mid-to-late forecast period (2023-2028), as pipeline products launching from 2020 onwards are expected to capture significant market share.
Key opinion leaders express excitement regarding the potential of the late-stage pipeline to expand access to therapy and address key unmet needs. In particular, Novartis' gene therapy Zolgensma (onasemnogene abeparvovec-xioi) represents a potentially transformative treatment option, as it is administered by a one-time intravenous infusion. This represents a strong differentiating factor from Spinraza, which requires intrathecal administration multiple times per year.
Zolgensma, which has already received approval in the US, is expected to emerge as the market leader in the APAC region by 2028 with sales of US$1.3bn across the (5GM) Australia, China, India, Japan and South Korea. Additionally, the launch of Roche's risdiplam, an SMN2 splicing modifier, is also eagerly anticipated owing to the drug's convenient oral administration route.
Although Spinraza's approval represented a major breakthrough in the field, there is still an unmet need for additional therapies that employ novel mechanisms of action and administration routes, which can translate into improvements in efficacy, accessibility, ease of use, and patient compliance.
The latest research report "Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028" helps in answering the following question with regards to Spinal Muscular Atrophy (SMA) and its therapeutic market in Asia Pacific.
The report will enable you to -